ADEQUACY OF THE CURRENT RECOMMENDED DOSAGE OF CIPROFLOXACIN IN PRETERM AND TERM NEONATES WITH SEPSIS
Journal Title: Journal of Drug Delivery and Therapeutics - Year 2017, Vol 7, Issue 3
Abstract
Objectives: To determine the percentage of neonates with sepsis, on treatment with standard recommended dose of intravenous ciprofloxacin, who had the serum ciprofloxacin Peak concentration: Minimum inhibitory concentration (Cmax:MIC), within the acceptable range. Design: Observational study design Intervention : In the Neonatology ICU, ciprofloxacin was initiated at a dose of 10mg/kg, twice daily in 95 neonates diagnosed with sepsis. On day 3 of ciprofloxacin, blood specimens were collected to measure the trough and peak concentrations of ciprofloxacin and was measured by high performance liquid chromatography. The MIC was measured if the blood culture was positive. When the blood culture was negative,the reference values for the MIC from ‘The Clinical and Laboratory Standard Institute Guidelines’ were adopted. Main outcomes: Minimum inhibitory concentration and serum concentrations of ciprofloxacin Results: Blood culture was positive in 14 babies. The mean (±SD) trough concentration of ciprofloxacin in term, preterm and very preterm neonates was 3.21(±1.99), 2.54 (±1.26) and 4.01(±1.80) μg/mL respectively. The mean (±SD) peak concentration of serum ciprofloxacinin term, preterm and very preterm neonates was, 12.55 (±4.945) 8.68(±3.61) and 12.07(±3.63) μg/mL, respectively. The percentage of neonates who achieved the acceptable Cmax /MIC ratio was predicted to be 74.07% if the strain was sensitive, 7.41% if intermediate and zero for resistant strains. Conclusion: The current recommended dose of intravenous ciprofloxacin in neonates in India may be adequate for treating sepsis due to susceptible organisms. For the treatment of sepsis caused by organisms with intermediate susceptibility, higher dosing regimens may be needed.
Authors and Affiliations
S Manvizhi
Keywords
Related Articles
- EP ID EP295548
- DOI 10.22270/jddt.v7i3.1446
- Views 85
- Downloads 0
PREPARATION, CHARACTERIZATION AND EVALUATION OF NEBIVOLOL LOADED CHITOSAN NANOPARTICLES
Nebivolol (NEB) is an antihypertensive drug with poor oral bioavailability (12%) in humans due to extensive first pass hepatic metabolism. Present work is an attempt to improve oral bioavailability of nebivolol by incorp...
FORMULATION AND EVALUATION OF MUCOADHESIVE BUCCAL TABLETS OF CANDESARTAN
Candesartan is an angiotensin II receptor antagonist and is widely  used in the management of hypertension to reduce cardiovascular mortality in patients with left ventricular dysfunc...
TECHNICAL CONSIDERATIONS OF FORCED DEGRADATION STUDIES OF NEW DRUG SUBSTANCES AND PRODUCT: REGULATORY PERSPECTIVES
Forced degradation studies of new drug substances and drug product are important to help develop and demonstrate specificity of stability indicating methods and provide knowledge about possible degradation pathways and d...
DOCKING STUDY OF CHRYSIN DERIVATIVES ON DIFFERENT TARGETS FOR ANTICANCER ACTIVITY
Some anticancer molecules using natural flavonoid chrysin were designed and docking studies were performed using Molegro Virtual Docker (MVD) software. Of the available crystal structures of the non- mutated Homo sapiens...
SOLUBILITY AND DISSOLUTION ENHANCEMENT OF WATER INSOLUBLE DRUG BY USING DIFFERENT HYDROPHILLIC CARRIERS AND FORMULATED INTO TABLET DOSAGE FORM
Rosuvastatin calcium is a BCS class II drug (low solubility and high permeability), used as a lipid lowering agent by acting as HMG CoA reductase inhibitor and it is used for the management of hyperlipidemia. Increase in...